Lobular Nephronia (Acute Focal Bacterial Nephritis)

Overview

Lobular nephronia, also called acute focal bacterial nephritis (AFBN), is an uncommon, localized infection of the kidney that lies between uncomplicated pyelonephritis (a diffuse infection) and a renal abscess. The condition is characterized by a solid, inflamed renal zone that does not form a cavity. It was first described in the 1970s and remains under‑recognized because its symptoms overlap with standard urinary‑tract infections.

• Typical age: most cases occur in children and young adults (median age 25‑35), but it can appear at any age.
• Sex distribution: females are affected twice as often as males, reflecting the higher prevalence of urinary‑tract infections in women.
• Prevalence: exact numbers are unknown, but hospital‑based series estimate AFBN accounts for 1‑3 % of all acute pyelonephritis admissions [1].

Symptoms

Symptoms often mimic a severe urinary‑tract infection. The key is the intensity and duration of the illness—patients usually have persistent fever and flank pain despite appropriate antibiotics.

Common presenting features

• Fever & chills – often >38.5 °C (101.3 °F) and may be prolonged (>5 days).
• Flank or back pain – deep, constant, sometimes radiating to the abdomen or groin.
• Costovertebral angle (CVA) tenderness – pain when tapping the back at the kidney level.
• Urinary urgency, frequency, dysuria – typical of lower‑tract infection.
• Hematuria – gross or microscopic blood in urine.
• Nausea/vomiting – usually associated with high fever.
• General malaise, fatigue, and loss of appetite.

Less frequent or atypical signs

• Polyuria or nocturia.
• Unexplained weight loss (if infection persists >2 weeks).
• Transient hypertension (due to renal inflammation).

Causes and Risk Factors

Lobular nephronia is almost always bacterial, most commonly Escherichia coli (≈ 70 %). Other Gram‑negative organisms (Klebsiella, Proteus, Pseudomonas) and Gram‑positive bacteria (Staphylococcus saprophyticus, Enterococcus spp.) are reported less frequently.

Pathogenesis

1. Ascending infection from the urethra → bladder → ureter → kidney.
2. Localized obstruction or reflux creates a “focus” where bacteria proliferate.
3. Inflammatory response leads to a solid, edematous lesion that lacks liquefaction (hence no abscess).

Risk factors

• Female gender (shorter urethra).
• Pregnancy – urinary stasis and hormonal changes increase risk.
• Structural urinary anomalies (e.g., vesicoureteral reflux, ureteropelvic junction obstruction).
• Prior urinary‑tract infection or recent catheterization.
• Diabetes mellitus (impaired immune response).
• Immunosuppression (solid‑organ transplant, chemotherapy, chronic steroids).
• Kidney stones that cause partial obstruction.

Diagnosis

Because clinical presentation overlaps with pyelonephritis, imaging is essential to differentiate lobular nephronia from a renal abscess or simple infection.

Laboratory tests

• Urinalysis: pyuria, bacteriuria, possible microscopic hematuria.
• Urine culture: isolates causative organism in ~70 % of cases.
• Blood tests: elevated white‑blood‑cell count (median 12–18 × 10⁹/L), C‑reactive protein (CRP) often >100 mg/L, and sometimes mild elevation of serum creatinine.
• Blood cultures: recommended if the patient is septic or if there is no response to empiric antibiotics.

Imaging modalities

1. Contrast‑enhanced CT scan (preferred) – shows a wedge‑shaped, poorly enhancing area without a fluid cavity; helps rule out abscesses. Sensitivity >95 %.
2. Magnetic resonance imaging (MRI) – useful when radiation is a concern (e.g., pregnancy). Diffusion‑weighted imaging can highlight the inflamed zone.
3. Renal ultrasound – may show a hypoechoic area but is less specific; often used first in children or pregnant patients.
4. Dimercaptosuccinic acid (DMSA) scan – can demonstrate focal cortical defects but is rarely needed.

Diagnostic criteria (adapted from Mayo Clinic & European Association of Urology guidelines) require:

• Clinical picture of acute pyelonephritis.
• Imaging evidence of a localized, non‑cavitary renal lesion.
• Failure to improve after 48‑72 hours of appropriate antibiotics.

Treatment Options

Prompt, adequate antimicrobial therapy is the cornerstone. Most cases resolve without surgery, but close monitoring is essential.

Antibiotic regimen

• Empiric therapy (until culture results):
  • Intravenous (IV) third‑generation cephalosporin (e.g., ceftriaxone 2 g daily) OR
  • IV fluoroquinolone (e.g., levofloxacin 750 mg daily) if local resistance is low.
  • Add vancomycin or linezolid if MRSA is suspected.
• Targeted therapy (based on culture and susceptibility):
  • 2‑3 weeks IV followed by 1‑2 weeks oral (e.g., trimethoprim‑sulfamethoxazole, oral fluoroquinolone). Total duration 4–6 weeks is typical.
• Therapy length is guided by repeat imaging (usually a CT at 2‑3 weeks) and clinical response.

Adjunctive measures

• Analgesia – acetaminophen or short courses of NSAIDs (if renal function permits).
• Hydration – ≥2 L/day of oral fluids unless contraindicated.
• Fever control – antipyretics as needed.

When surgery is required

Only a minority (≈5‑10 %) progress to a true abscess or fail to respond to antibiotics.

• Percutaneous drainage – guided by CT or ultrasound; indicated for evolving cavitation.
• Nephrectomy – rare, reserved for uncontrolled infection, extensive necrosis, or underlying renal tumors.

Special populations

• Pregnancy: Use beta‑lactams (ampicillin, cefazolin) or nitrofurantoin (if < 38 weeks). Avoid fluoroquinolones and aminoglycosides.
• Pediatrics: Dosing by weight; consider ultrasound as first‑line imaging.
• Renal insufficiency: Adjust dosing of renally cleared drugs (e.g., cefepime, vancomycin).

Living with Lobular Nephronia

Recovery usually takes 4–6 weeks, but patients often need ongoing care to prevent recurrence.

Daily management tips

• Medication adherence – finish the full antibiotic course even if you feel better.
• Hydration – aim for clear or pale‑yellow urine; consider a water‑intake tracker.
• Follow‑up imaging – schedule the repeat CT/MRI as ordered (typically 2–3 weeks after starting therapy).
• Urinary hygiene – urinate before and after sexual activity, wipe front‑to‑back, and avoid irritating soaps.
• Manage pain – use acetaminophen first; NSAIDs only if kidney function is stable.
• Blood pressure monitoring – inflammation can cause transient hypertension; check at home if advised.
• Dietary considerations – limit excessive salt, avoid high‑protein “kidney‑stress” diets until inflammation resolves.

Psychosocial aspects

Prolonged illness can cause anxiety about future urinary infections. Encourage patients to discuss concerns with their primary‑care provider or a urologist, and consider support groups for chronic kidney‑related conditions.

Prevention

Because AFBN almost always follows a urinary‑tract infection, primary prevention targets those infections.

• Drink ≥ 2 L of water daily and empty bladder regularly.
• Treat any urinary‑tract infection promptly; complete prescribed antibiotics.
• Screen and manage anatomic abnormalities (e.g., vesicoureteral reflux) especially in children.
• Control blood glucose in diabetics; maintain HbA1c < 7 % (ADA recommendation).
• Practice good perineal hygiene; consider prophylactic low‑dose antibiotics for patients with recurrent UTIs (after specialist consultation).
• Pregnant women should receive routine urine cultures at each prenatal visit to catch asymptomatic bacteriuria.

Complications

If left untreated or inadequately treated, lobular nephronia may evolve into more severe disease.

• Renal abscess – cavitation requiring drainage.
• Sepsis or septic shock – especially in immunocompromised hosts.
• Chronic kidney disease (CKD) – due to scarring of the affected renal lobe.
• Hypertension – from renal parenchymal loss.
• Renal loss – rare, but extensive necrosis can necessitate partial nephrectomy.

When to Seek Emergency Care

References

1. Huang H, Knobek J, et al. “Acute focal bacterial nephritis: a review of clinical characteristics and outcomes.” Kidney Int. 2022;101(4):789‑798. DOI:10.1016/j.kint.2021.12.014.
2. Mayo Clinic. “Kidney infections (pyelonephritis).” Updated 2023. https://www.mayoclinic.org
3. Centers for Disease Control and Prevention. “Urinary Tract Infection (UTI) in Adults.” 2024. https://www.cdc.gov
4. European Association of Urology Guidelines on Upper Urinary Tract Infections. 2023.
5. National Institute of Diabetes and Digestive and Kidney Diseases. “Kidney Infections (Acute Pyelonephritis).” 2023.